Description de l'entreprise
Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Patrick Amstutz |
| Conseil d'administration |
| Alexander Zürcher, Philippe Legenne, M.D., MBA, Dr. Michael Tobias Stumpp, Renate Gloggner, Anne Goubier, D.V.M., Ph.D., Robert Hendriks, Dr. Julia Hepp, Michael Pitzner, Seth Lewis, Dr. Daniel Steiner, Baris Arican, MBA |
| Conseil de surveillance |
| William Burns, Dr. Patrick Amstutz, Dr. Agnete Fredriksen, Dominik Höchli, M.D., Steven H. Holtzman, Sandip Kapadia, Dr. Vito L. Palombella, Dr. Michal Vasconelles |
Données de l'entreprise
| Nom: |
Molecular Partners AG |
| Adresse: |
Wagistrasse 14,CH-8952 Zürich-Schlieren |
| Téléphone: |
+41-44-755-77-00 |
| Fax: |
+41-44-755-77-07 |
| Courriel: |
-
|
| Internet: |
www.molecularpartners.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
58.15% |
| IPO date: |
- |
Relations avec les investisseurs
